285. ファンコニ貧血 Disease details / Clinical trials / Drug dev / DR info

Abatacept
   Emory University
      2014   Phase 1   NCT01917708   United States
Afatinib
   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2024   Phase 1/Phase 2   NCT06648096   Germany;Spain
Alcohol
   Masonic Cancer Center, University of Minnesota
      2022   -   NCT05973656   United States
Alefacept
   Emory University
      2010   -   NCT01319851   United States
Alemtuzumab
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
Allogeneic bone marrow transplantation
   Fred Hutchinson Cancer Research Center
      2007   Phase 2   NCT00453388   Brazil;United States
      2000   Phase 1   NCT00093743   United States
      1998   Phase 1   NCT00317876   Brazil;United States
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
   University of California, San Francisco
      2000   Phase 1/Phase 2   NCT00305708   United States
Allogeneic hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Research Center
      2000   Phase 1   NCT00093743   United States
   Roswell Park Cancer Institute
      2009   -   NCT00856388   United States
Amcell clinimacs
   Children's Hospital Medical Center, Cincinnati
      2007   Phase 1/Phase 2   NCT00479115   United States
AMD3100
   Children's Hospital Medical Center, Cincinnati
      2007   Phase 1/Phase 2   NCT00479115   United States
ANTI-CD45
   Baylor College of Medicine
      2002   Phase 1   NCT00586274   United States
ANTI-thymocyte globulin
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00258427   United States
      2000   Phase 1/Phase 2   NCT00630253   United States
      1999   -   NCT00290628   United States
   Memorial Sloan Kettering Cancer Center
      2018   Phase 2   NCT03600909   United States
   Milton S. Hershey Medical Center
      2003   Phase 2   NCT00084695   United States
   Roswell Park Cancer Institute
      2009   -   NCT00856388   United States
      2002   Phase 2   NCT00053989   United States
   University of California, San Francisco
      2000   Phase 1/Phase 2   NCT00305708   United States
AP1903
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 1;Phase 2   EUCTR2016-003226-16-IT   Italy
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom
      2014   Phase 1;Phase 2   EUCTR2014-000584-41-IT   Italy;Spain;United Kingdom
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom
ATG
   Medical College of Wisconsin
      2009   Phase 2   NCT01071239   United States
   Memorial Sloan Kettering Cancer Center
      2009   Phase 2   NCT00987480   United States
Biopsy
   OHSU Knight Cancer Institute
      2002   -   NCT00899795   United States
      2002   -   NCT00896740   United States
   University Hospital Freiburg
      2007   -   NCT00499070   Austria;Belgium;Czech Republic;Denmark;Germany;Ireland;Italy;Netherlands;Poland;Spain;Switzerland
Biospecimen collection
   Academic and Community Cancer Research United
      2020   Phase 2   NCT04042831   United States
   Masonic Cancer Center, University of Minnesota
      2022   -   NCT05973656   United States
Bone marrow aspiration
   Fred Hutchinson Cancer Center
      2012   Phase 1   NCT01331018   United States
   Hospital Infantil Universitario Niño Jesús, Madrid, Spain
      2016   Phase 1/Phase 2   NCT03157804   Spain
Bone marrow transplantation
   Masonic Cancer Center, University of Minnesota
      2006   Phase 2/Phase 3   NCT00352976   United States
BPX-501 cells
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom
      2014   Phase 1;Phase 2   EUCTR2014-000584-41-IT   Italy;Spain;United Kingdom
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom
BPX-501 T cells
   Bellicum Pharmaceuticals
      2014   Phase 1/Phase 2   NCT02065869   Germany;Italy;Spain;United Kingdom;United States
Breath test
   Masonic Cancer Center, University of Minnesota
      2022   -   NCT05973656   United States
Busulfan
   Children's Hospital Medical Center, Cincinnati
      2014   Phase 2   NCT02143830   United States
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      2002   Phase 2   NCT00258427   United States
      1999   -   NCT00290628   United States
   Medical College of Wisconsin
      2009   Phase 2   NCT01071239   United States
   Memorial Sloan Kettering Cancer Center
      2018   Phase 2   NCT03600909   United States
      2009   Phase 2   NCT00987480   United States
   Milton S. Hershey Medical Center
      2003   Phase 2   NCT00084695   United States
   University of California, San Francisco
      2000   Phase 1/Phase 2   NCT00305708   United States
Campath 1H
   Baylor College of Medicine
      2002   Phase 1   NCT00586274   United States
CD34 selected haploidentical pbsct
   Baylor College of Medicine
      2002   Phase 1   NCT00586274   United States
CD34+ cell enriched stem cell graft
   University of Florida
      2025   -   NCT06731036   -
CD34+ cells
   FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO NIÑO JESUS
      2013   -   EUCTR2011-006100-12-ES   Spain
CD34+ selected cells
   Neena Kapoor, M.D.
      2011   -   NCT02127905   United States
CD34+cells
   Rocket Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002502-31-GB   Spain;United Kingdom
      2018   Phase 2   EUCTR2018-002502-31-ES   Spain
Chemotherapy
   Children's Hospital Medical Center, Cincinnati
      2009   Phase 2   NCT01082133   United States
Clinimacs device
   Medical College of Wisconsin
      2009   Phase 2   NCT01071239   United States
   Memorial Sloan Kettering Cancer Center
      2009   Phase 2   NCT00987480   United States
Clinimacs prodigy system
   Porteus, Matthew, MD
      2021   Phase 1/Phase 2   NCT04784052   United States
Computed tomography
   Academic and Community Cancer Research United
      2020   Phase 2   NCT04042831   United States
Cyclophosphamide
   Children's Hospital Medical Center, Cincinnati
      2014   Phase 2   NCT02143830   United States
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States
   Fred Hutchinson Cancer Research Center
      2007   Phase 2   NCT00453388   Brazil;United States
      1998   Phase 1   NCT00317876   Brazil;United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      2006   Phase 2/Phase 3   NCT00352976   United States
      2002   Phase 2   NCT00258427   United States
      2000   Phase 1/Phase 2   NCT00630253   United States
      1999   -   NCT00290628   United States
   Medical College of Wisconsin
      2009   Phase 2   NCT01071239   United States
   Memorial Sloan Kettering Cancer Center
      2018   Phase 2   NCT03600909   United States
      2009   Phase 2   NCT00987480   United States
      2001   -   NCT00595127   United States
   Milton S. Hershey Medical Center
      2003   Phase 2   NCT00084695   United States
   Porteus, Matthew, MD
      2021   Phase 1/Phase 2   NCT04784052   United States
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
Cyclophosphamide, fludarabine
   Masonic Cancer Center, University of Minnesota
      2004   Phase 1/Phase 2   NCT00167206   United States
Cyclosporine
   Fred Hutchinson Cancer Research Center
      2007   Phase 2   NCT00453388   Brazil;United States
      2000   Phase 1   NCT00093743   United States
      1998   Phase 1   NCT00317876   Brazil;United States
   Masonic Cancer Center, University of Minnesota
      2000   Phase 1/Phase 2   NCT00630253   United States
      1999   -   NCT00290628   United States
   Memorial Sloan Kettering Cancer Center
      2009   Phase 2   NCT00987480   United States
Cytogenetic analysis
   OHSU Knight Cancer Institute
      2002   -   NCT00899795   United States
Danazol
   Boston Children's Hospital
      2009   Phase 1/Phase 2   NCT01001598   United States
Depleted stem cell transplant
   Porteus, Matthew, MD
      2021   Phase 1/Phase 2   NCT04784052   United States
Donor mobilized pbsc infusion
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
Eltrombopag
   Julian Sevilla
      2020   Phase 2   NCT06045052   Spain
   National Heart, Lung, and Blood Institute (NHLBI)
      2018   Phase 2   NCT03206086   United States
Enbrel*SC 4FL 25MG+4SIR 1ML
   ISTITUTO GIANNINA GASLINI
      2005   -   EUCTR2004-004914-18-IT   Italy
Etanercept
   Children's Hospital Medical Center, Cincinnati
      2005   Early Phase 1   NCT00965666   United States
   ISTITUTO GIANNINA GASLINI
      2005   -   EUCTR2004-004914-18-IT   Italy
Filgrastim
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2014-005264-14-FR   France
   Fred Hutchinson Cancer Center
      2012   Phase 1   NCT01331018   United States
   Great Ormond Street Hospital NHS foundation Trust
      2015   Phase 2   EUCTR2014-004272-29-GB   France;Spain;United Kingdom
   Hospital Infantil Universitario Niño Jesús, Madrid, Spain
      2016   Phase 1/Phase 2   NCT03157804   Spain
   Hospital Universitari Vall d'Hebron Research Institute
      2013   Phase 2   NCT02931071   Spain
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00258427   United States
      2000   Phase 1/Phase 2   NCT00630253   United States
      1999   -   NCT00290628   United States
Flow cytometry
   OHSU Knight Cancer Institute
      2002   -   NCT00899795   United States
   University Hospital Freiburg
      2007   -   NCT00499070   Austria;Belgium;Czech Republic;Denmark;Germany;Ireland;Italy;Netherlands;Poland;Spain;Switzerland
Fludarabine
   Baylor College of Medicine
      2002   Phase 1   NCT00586274   United States
   Children's Hospital Medical Center, Cincinnati
      2014   Phase 2   NCT02143830   United States
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      2006   Phase 2/Phase 3   NCT00352976   United States
      2000   Phase 1/Phase 2   NCT00630253   United States
   Medical College of Wisconsin
      2009   Phase 2   NCT01071239   United States
   Memorial Sloan Kettering Cancer Center
      2018   Phase 2   NCT03600909   United States
      2009   Phase 2   NCT00987480   United States
      2001   -   NCT00595127   United States
   Porteus, Matthew, MD
      2021   Phase 1/Phase 2   NCT04784052   United States
   University of California, San Francisco
      2011   -   NCT01316549   United States
Fludarabine phosphate
   Fred Hutchinson Cancer Research Center
      2007   Phase 2   NCT00453388   Brazil;United States
      2000   Phase 1   NCT00093743   United States
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00258427   United States
   Milton S. Hershey Medical Center
      2003   Phase 2   NCT00084695   United States
   Roswell Park Cancer Institute
      2009   -   NCT00856388   United States
      2002   Phase 2   NCT00053989   United States
   University of California, San Francisco
      2000   Phase 1/Phase 2   NCT00305708   United States
Fluorescence IN situ hybridization
   OHSU Knight Cancer Institute
      2002   -   NCT00899795   United States
FP-045
   Foresee Pharmaceuticals Co., Ltd.
      2023   Phase 1/Phase 2   NCT04522375   Turkey;United States
G-CSF
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2014-005264-14-FR   France
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 1/Phase 2   NCT02678533   France
   Children's Hospital Medical Center, Cincinnati
      2014   Phase 2   NCT02143830   United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
   Memorial Sloan Kettering Cancer Center
      2018   Phase 2   NCT03600909   United States
GENE-modified autologous stem cells
   Shenzhen Geno-Immune Medical Institute
      2017   -   NCT03351868   China
Genetically engineered hematopoietic stem progenitor cells
   Fred Hutchinson Cancer Center
      2012   Phase 1   NCT01331018   United States
Genetically engineered hematopoietic stem/progenitor cells
   Hospital Infantil Universitario Niño Jesús, Madrid, Spain
      2016   Phase 1/Phase 2   NCT03157804   Spain
Graft-versus-tumor induction therapy
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
Hematopoietic stem cell transplant
   Masonic Cancer Center, University of Minnesota
      2004   Phase 1/Phase 2   NCT00167206   United States
Hematopoietic stem cell transplantation
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00258427   United States
      2000   Phase 1/Phase 2   NCT00630253   United States
Horse ANTI-thymocyte globulin
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States
Human whole exome
   Xiaofan Zhu
      2013   -   NCT01995305   China
Immunologic technique
   University Hospital Freiburg
      2007   -   NCT00499070   Austria;Belgium;Czech Republic;Denmark;Germany;Ireland;Italy;Netherlands;Poland;Spain;Switzerland
JSP191
   Porteus, Matthew, MD
      2021   Phase 1/Phase 2   NCT04784052   United States
Laboratory biomarker analysis
   Fred Hutchinson Cancer Center
      2012   Phase 1   NCT01331018   United States
   Fred Hutchinson Cancer Research Center
      2007   Phase 2   NCT00453388   Brazil;United States
   Hospital Infantil Universitario Niño Jesús, Madrid, Spain
      2016   Phase 1/Phase 2   NCT03157804   Spain
Leukapheresis
   Fred Hutchinson Cancer Center
      2012   Phase 1   NCT01331018   United States
Magnetic resonance imaging
   Academic and Community Cancer Research United
      2020   Phase 2   NCT04042831   United States
Melphalan
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      1999   -   NCT00290628   United States
   Milton S. Hershey Medical Center
      2003   Phase 2   NCT00084695   United States
   Roswell Park Cancer Institute
      2009   -   NCT00856388   United States
Metformin
   Ain Shams University
      2022   Phase 3   NCT06519786   Egypt
Metformin HCL
   Boston Children's Hospital
      2018   Phase 2   NCT03398824   United States
Methotrexate
   Fred Hutchinson Cancer Research Center
      1998   Phase 1   NCT00317876   Brazil;United States
Methylprednisolone
   Fred Hutchinson Cancer Center
      2012   Phase 1   NCT01331018   United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      2002   Phase 2   NCT00258427   United States
      2000   Phase 1/Phase 2   NCT00630253   United States
      1999   -   NCT00290628   United States
   Milton S. Hershey Medical Center
      2003   Phase 2   NCT00084695   United States
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
Microarray analysis
   OHSU Knight Cancer Institute
      2002   -   NCT00896740   United States
Miltenyi clinimacs
   Children's Hospital Medical Center, Cincinnati
      2009   Phase 2   NCT01082133   United States
Mozobil
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2014-005264-14-FR   France
   Great Ormond Street Hospital NHS foundation Trust
      2015   Phase 2   EUCTR2014-004272-29-GB   France;Spain;United Kingdom
Mycophenolate mofetil
   Fred Hutchinson Cancer Research Center
      2007   Phase 2   NCT00453388   Brazil;United States
      2000   Phase 1   NCT00093743   United States
   Masonic Cancer Center, University of Minnesota
      2006   Phase 2/Phase 3   NCT00352976   United States
      2000   Phase 1/Phase 2   NCT00630253   United States
      1999   -   NCT00290628   United States
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
Neupogen
   Great Ormond Street Hospital NHS foundation Trust
      2015   Phase 2   EUCTR2014-004272-29-GB   France;Spain;United Kingdom
Nonmyeloablative allogeneic hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Research Center
      2007   Phase 2   NCT00453388   Brazil;United States
      1998   Phase 1   NCT00317876   Brazil;United States
Olaparib
   Academic and Community Cancer Research United
      2020   Phase 2   NCT04042831   United States
   Baptist Health South Florida
      2020   Phase 2   NCT04483544   United States
Oxandrolone
   Children's Hospital Medical Center, Cincinnati
      2004   Phase 1   NCT00243399   United States
Pembrolizumab
   Baptist Health South Florida
      2020   Phase 2   NCT04483544   United States
Peripheral blood stem cell
   Children's Hospital Medical Center, Cincinnati
      2014   Phase 2   NCT02143830   United States
Peripheral blood stem cell transplantation
   Fred Hutchinson Cancer Research Center
      2000   Phase 1   NCT00093743   United States
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
   University of California, San Francisco
      2000   Phase 1/Phase 2   NCT00305708   United States
Plerixafor
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 1/Phase 2   NCT02678533   France
   Fred Hutchinson Cancer Center
      2012   Phase 1   NCT01331018   United States
   Great Ormond Street Hospital NHS foundation Trust
      2015   Phase 2   EUCTR2014-004272-29-GB   France;Spain;United Kingdom
   Hospital Infantil Universitario Niño Jesús, Madrid, Spain
      2016   Phase 1/Phase 2   NCT03157804   Spain
   Hospital Universitari Vall d'Hebron Research Institute
      2013   Phase 2   NCT02931071   Spain
PLérixafor
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2014-005264-14-FR   France
Polymerase chain reaction
   University Hospital Freiburg
      2007   -   NCT00499070   Austria;Belgium;Czech Republic;Denmark;Germany;Ireland;Italy;Netherlands;Poland;Spain;Switzerland
Prednisone
   Fred Hutchinson Cancer Center
      2012   Phase 1   NCT01331018   United States
Quercetin
   Children's Hospital Medical Center, Cincinnati
      2018   Phase 2   NCT03476330   United States
      2012   Phase 1   NCT01720147   United States
Rabbit
   Memorial Sloan Kettering Cancer Center
      2018   Phase 2   NCT03600909   United States
   Porteus, Matthew, MD
      2021   Phase 1/Phase 2   NCT04784052   United States
Rabbit ANTI-thymocyte globulin
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States
Rabbit ATG
   Children's Hospital Medical Center, Cincinnati
      2014   Phase 2   NCT02143830   United States
Radiation therapy
   Masonic Cancer Center, University of Minnesota
      1999   -   NCT00290628   United States
   Milton S. Hershey Medical Center
      2003   Phase 2   NCT00084695   United States
   University of California, San Francisco
      2000   Phase 1/Phase 2   NCT00305708   United States
Ratg
   Porteus, Matthew, MD
      2021   Phase 1/Phase 2   NCT04784052   United States
Retrovirus construct
   Boston Children’s Hospital
      2004   Phase 1   NCT00272857   United States
Rimiducid
   Bellicum Pharmaceuticals
      2017   Phase 1/Phase 2   NCT03733249   Italy;Saudi Arabia;United Kingdom
      2014   Phase 1/Phase 2   NCT02065869   Germany;Italy;Spain;United Kingdom;United States
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom
Rituximab
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
   Porteus, Matthew, MD
      2021   Phase 1/Phase 2   NCT04784052   United States
Rivogenlecleucel
   Bellicum Pharmaceuticals
      2017   Phase 1/Phase 2   NCT03733249   Italy;Saudi Arabia;United Kingdom
   Bellicum Pharmaceuticals, Inc.
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom
Rivogenleucleucel
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom
RP-L102
   Rocket Pharmaceuticals Inc.
      2020   Phase 2   NCT04248439   United States
      2019   Phase 2   NCT04069533   Spain;United Kingdom
      2019   Phase 1   NCT03814408   United States
   Rocket Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002502-31-GB   Spain;United Kingdom
      2018   Phase 2   EUCTR2018-002502-31-ES   Spain
Sargramostim
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
Sirolimus
   Masonic Cancer Center, University of Minnesota
      2006   Phase 2/Phase 3   NCT00352976   United States
T cell infusion
   Baylor College of Medicine
      2002   Phase 1   NCT00586274   United States
Tacrolimus
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
TBI
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
   Memorial Sloan Kettering Cancer Center
      2001   -   NCT00595127   United States
THE clinimacs device
   Memorial Sloan Kettering Cancer Center
      2018   Phase 2   NCT03600909   United States
Therapeutic allogeneic lymphocytes
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
Thiotepa
   University of California, San Francisco
      2017   -   NCT03609840   United States
Thymic shielding during radiation
   Masonic Cancer Center, University of Minnesota
      2004   Phase 1/Phase 2   NCT00167206   United States
Thymoglobulin
   Porteus, Matthew, MD
      2021   Phase 1/Phase 2   NCT04784052   United States
Total body irradiation
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      2006   Phase 2/Phase 3   NCT00352976   United States
      2004   Phase 1/Phase 2   NCT00167206   United States
   Memorial Sloan Kettering Cancer Center
      2001   -   NCT00595127   United States
Total-body irradiation
   Fred Hutchinson Cancer Research Center
      2007   Phase 2   NCT00453388   Brazil;United States
      2000   Phase 1   NCT00093743   United States
   Roswell Park Cancer Institute
      2009   -   NCT00856388   United States
Transduced CD34+ cells
   National Heart, Lung, and Blood Institute (NHLBI)
      1993   Phase 1   NCT00001399   United States
Umbilical cord blood transplantation
   Masonic Cancer Center, University of Minnesota
      1999   -   NCT00290628   United States
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States
   University of California, San Francisco
      2000   Phase 1/Phase 2   NCT00305708   United States
Whole genomic
   Xiaofan Zhu
      2013   -   NCT01995305   China
Zarzio
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2014-005264-14-FR   France